Ten years ago, diagnosis of chronic lymphocytic leukemia (CLL) meant treatment with chemotherapy and, for most patients, a shorter life expectancy than before diagnosis. Today, those are no longer foregone conclusions. The past decade has seen the FDA approve a handful of new targeted therapies ...
CHRONIC lymphocytic leukemiaIMMUNOTHERAPYANTINEOPLASTIC agentsCANCER chemotherapyINTRAVENOUS therapyPROGRESSION-free survivalZusammenfassung: Background: In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetecta...
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912–4920. Article Google Scholar Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et ...
Getting cancer or leukemia is a comprehensive process, and so it healing yourself enough so that you can continue to live a good life. All the other pillars that create health matter: clean food, clean air, clean water, reduced/managed stress, good sleep, meditation, finding joy in life; ...
“You’ve been skating uphill for nine years.” (I’m editing today; it’s been fourteen years.) I kind of like that. It makes me feel much more athletic than I really am. And despite the fact that I still have this leukemia thing – despite all my efforts — it ...
We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic leukemia (CLL). Eight hundred patients with untreated-stage Binet A disease were enrolled ...
ORLANDO, Florida ― The investigational agent venetoclax (under development by AbbVie in partnership with Genentech/Roche) achieved high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), which is associated with a very poor prognosis. ...
chronic lymphocytic leukemia; older patient; Bruton tyrosine kinase; BCL2; cost-effectiveness1. Introduction Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia, representing 1% of all cancer cases [1]. The reported incidence is 4.7 cases per 100,000, and the ...
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020, 34, 787–798. [Google Scholar] [CrossRef] [PubMed] [Green Version] O’Brien, S.; Jones, J.A.; Coutre, S.E.; Mato,...